The nature and duration of treatment for GAD
- 1 December 1998
- journal article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 98 (s393) , 109-117
- https://doi.org/10.1111/j.1600-0447.1998.tb05975.x
Abstract
It is becoming increasingly evident that GAD is a chronic condition with repeated acute-on-chronic episodes. Treatment in the short term relies on the benzodiazepines, which are rapid in action, providing substantial symptomatic relief with a low incidence of side-effects and low toxicity in overdose. The risk of more serious unwanted effects in the long term, including some risk of physical dependence, has led to a move towards alternative treatments both pharmacological and psychotherapeutic. Antidepressants are being used on a long-term basis, but data are sparse to confirm their efficacy in GAD. Anxiety management and cognitive-behavioural techniques are rivalling pharmacotherapy in popularity. None the less, research seeking optimal ways of combining therapies remains an urgent priority.Keywords
This publication has 64 references indexed in Scilit:
- DSM-IVCNS Drugs, 1995
- Newer and Older Monoamine Oxidase InhibitorsCNS Drugs, 1995
- Abecarnil in Generalised Anxiety DisorderCNS Drugs, 1995
- Guidelines for the Rational Use of BenzodiazepinesDrugs, 1994
- Treating the Somatic Symptoms of AnxietyCNS Drugs, 1994
- BenzodiazepinesCNS Drugs, 1994
- Anxiolytic Potential of Benzodiazepine Receptor Partial AgonistsCNS Drugs, 1994
- Prescribing and Use of Benzodiazepines: An Epidemiologic PerspectiveJournal of Psychoactive Drugs, 1992
- 5-HT1A Partial AgonistsDrugs, 1991